ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression

doi:10.1186/1471-2407-8-179

BMC Cancer

Volume 8

Viewing options:

Abstract
Full text
PDF (597KB)

Associated material:

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Fritzsche FR
Wassermann K
Jung M
Tölle A
Kristiansen I
Lein M
Johannsen M
Dietel M
Jung K
Kristiansen G

on PubMed

Fritzsche FR
Wassermann K
Jung M
Tölle A
Kristiansen I
Lein M
Johannsen M
Dietel M
Jung K
Kristiansen G
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research article

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression

Florian R Fritzsche¹^,3^* , Kirsten Wassermann¹^* , Monika Jung² , Angelika Tölle² , Ilka Kristiansen¹ , Michael Lein² , Manfred Johannsen² , Manfred Dietel¹ , Klaus Jung² and Glen Kristiansen³

¹Institute of Pathology, Charité – Universitätsmedizin Berlin, Berlin, Germany

²Institute of Urology, Charité – Universitätsmedizin Berlin, Berlin, Germany

³Institute of Surgical Pathology, UniversitätsSpital Zürich, Zurich, Switzerland

author email corresponding author email* Contributed equally

BMC Cancer 2008, 8:179doi:10.1186/1471-2407-8-179


Published:	26 June 2008

Abstract

Background

A Disintegrin And Metalloprotease (ADAM) 9 has been implicated in tumour progression of various solid tumours, however, little is known about its role in renal cell carcinoma. We evaluated the expression of ADAM9 on protein and transcript level in a clinico-pathologically characterized renal cell cancer cohort.

Methods

108 renal cancer cases were immunostained for ADAM9 on a tissue-micro-array. For 30 additional cases, ADAM9 mRNA of microdissected tumour and normal tissue was analyzed via quantitative RT-PCR. SPSS 14.0 was used to apply crosstables (Fisher's exact test and χ²-test), correlations and univariate as well as multivariate survival analyses.

Results

ADAM9 was significantly up-regulated in renal cancer in comparison to the adjacent normal tissue on mRNA level. On protein level, ADAM9 was significantly associated with higher tumour grade, positive nodal status and distant metastasis. Furthermore, ADAM9 protein expression was significantly associated with shortened patient survival in the univariate analysis.

Conclusion

ADAM9 is strongly expressed in a large proportion of renal cell cancers, concordant with findings in other tumour entities. Additionally, ADAM9 expression is significantly associated with markers of unfavourable prognosis. Whether the demonstrated prognostic value of ADAM9 is independent from other tumour parameters will have to be verified in larger study cohorts.